贝伐珠单抗联合培美曲塞治疗老年晚期肺腺癌的临床疗效研究

Study on clinical efficacy of bevacizumab combined with pemetrexed in the treatment of advanced lung adenocarcinoma in the elderly

目的探究老年晚期肺腺癌患者治疗过程中采用贝伐珠单抗联合培美曲塞治疗的效果。方法76例老年晚期肺腺癌患者,以计算机表法分为对照组和研究组,每组38例。对照组给予常规治疗,研究组联用贝伐珠单抗、培美曲塞治疗。比较两组患者免疫功能指标[免疫球蛋白M(IgM)、免疫球蛋白A(IgA)]、肿瘤标志物[癌胚抗原(CEA)、细胞角质蛋白19(CK-19)、血管内皮生长因子(VEGF)]、治疗效果、不良反应发生情况。结果治疗后,研究组患者IgM、IgA水平分别为(0.89±0.12)、(2.24±0.15)g/L,比对照组的(0.68±0.09)、(2.01±0.12)g/L高,差异有统计学意义(P<0.05)。治疗后,研究组患者CEA、CK-19、VEGF水平分别为(92.53±0.58)μg/L、(122.45±5.86)μg/L、(35.48±2.54)pg/ml,比对照组的(114.65±8.65)μg/L、(159.35±5.64)μg/L、(89.86±5.89)pg/ml低,差异有统计学意义(P<0.05)。研究组患者治疗总有效率92.11%比对照组的68.42%高,差异有统计学意义(P<0.05)。研究组患者不良反应发生率10.53%比对照组的31.58%低,差异有统计学意义(P<0.05)。结论临床使用贝伐珠单抗联合培美曲塞治疗老年晚期肺腺癌效果显著,能提高患者免疫功能,使免疫细胞有效抵抗恶性肿瘤的增殖与发展,降低肿瘤标志物水平,减少患者不良反应发生风险,提高患者疾病预后,能够面向基层医疗机构进行推广,值得临床使用。

Objective To explore the effect of bevacizumab combined with pemetrexed in the treatment of advanced lung adenocarcinoma in the elderly.Methods 76 patients with advanced lung adenocarcinoma were selected.They were divided into a control group and a study group using computer table method,with 38 patients in each group.The control group received routine treatment,and the study group received combined treatment with bevacizumab and pemetrexed.Patients in both groups were comared in terms of immune function[immunoglobulin M(IgM),immunoglobulin A(IgA)],tumor markers[carcinoembryonic antigen(CEA),cytokeratin-19(CK-19),cascular endothelial growth factor(VEGF)],treatment efficacy,and adverse reactions.Results After treatment,IgM and IgA levels in the study group were(0.89±0.12)and(2.24±0.15)g/L,which were higher than(0.68±0.09)and(2.01±0.12)g/L in the control group,and the difference was statistically significant(P<0.05).After treatment,CEA,CK-19 and VEGF levels in the study group were(92.53±0.58)μg/L,(122.45±5.86)μg/L and(35.48±2.54)pg/ml,which were lower than(114.65±8.65)μg/L,(159.35±5.64)μg/L and(89.86±5.89)pg/ml in the control group,and the difference was statistically significant(P<0.05).The total effective rate was 92.11%in the study group,which was higher than 68.42%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 10.53%,which was lower than 31.58%in the control group,and the difference was statistically significant(P<0.05).Conclusion The clinical use of bevacizumab and pemetrexed in the treatment of advanced lung adenocarcinoma has a significant effect.The combination therapy can improve the patient's immune function,enable the patient's immune cells to effectively resist the proliferation and development of malignant tumors,reduce the level of tumor markers,avoid the risk of adverse reactions in patients,and improve the patient's disease prognosis.It can be promoted to grassroots medical institutions and is worth clinical use.